<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02649608</url>
  </required_header>
  <id_info>
    <org_study_id>16779A</org_study_id>
    <nct_id>NCT02649608</nct_id>
  </id_info>
  <brief_title>An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients</brief_title>
  <official_title>Interventional, Open-label, Exploratory Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AE04621 and the Active Metabolite Lu AA40326 After Ascending Oral Doses of Lu AE04621 to Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability, pharmacokinetics, and efficacy of the Lu AE04621 and
      metabolite after ascending oral doses of Lu AE04621 in patients with Parkinson`s Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study comprised 5 cohorts (Cohorts 1 to 5), with each cohort consisting of 3 patients
      with Parkinson's disease (men and/or women). Each patient will be treated for 3 or 4 days,
      with increasing dose each day.

      Dosing regimen will be decided at a dosing conferences. Dose levels can be increased,
      maintained or reduced both between cohorts but also within same cohort. The results are
      presented by dose level and reflect the actual doses administered.

      A follow-up safety visit was scheduled approximately 7 days after the last dose of IMP.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study comprised 5 cohorts (Cohorts 1 to 5), with each cohort consisting of 3 patients (men and/or women). The dosing regimen planned for Cohort 1 was a dose of 0.2 mg Lu AE04621 on Day 1 followed by a dose of 0.4 mg Lu AE04621 on Day 2, and a dose of 0.6 mg Lu AE04621 on Day 3. • The dosing regimen planned for Cohort 2 was 0.4 mg Lu AE04621 on Day 1 followed by a dose of 0.6 mg Lu AE04621 on Day 2, and a dose of 0.8 mg Lu AE04621 on Day 3. The dosing regimen planned for Cohort 3 was 0.2 mg Lu AE04621 on Day 1 followed by a dose of 0.4 mg Lu AE04621 on Day 2, a dose of 0.6 mg Lu AE04621 on Day 3, and a dose of 1.0 mg Lu AE04621 on Day 4. The dosing regimen planned for Cohorts 4 and 5 was 0.2 mg Lu AE04621 on Day 1 followed by a dose of 0.4 mg Lu AE04621 on Day 2, a dose of 0.6 mg Lu AE04621 on Day 3, and a dose of 1.2 mg Lu AE04621 on Day 4. The results are presented by dose groups and are based on the actual doses administered.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability Based on the Safety Variables (Adverse Events, Clinical Safety Laboratory Tests, Vital Signs, Weight, and ECG)</measure>
    <time_frame>Baseline to day 11</time_frame>
    <description>Number of patients with an adverse event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve (AUC(0-24 Hours)) for Lu AE04621</measure>
    <time_frame>From dosing to up to 24 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for Lu AE04621</measure>
    <time_frame>From dosing to up to 24 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Elimination Half-life of Lu AE04621 in Plasma (t½)</measure>
    <time_frame>From dosing to up to 24 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Onset of &quot;ON&quot; Time After Lu AE04621 Administration</measure>
    <time_frame>From dosing to 90 minutes after dosing</time_frame>
    <description>&quot;ON&quot; state is defined as a period of good control of parkinsonian features with relatively good overall function and mobility. Motor fluctuation assessments are patient-reported outcomes, and guidance will be given to the patients on how to complete them. Date and time will be registered when the patient turns to &quot;ON&quot; and &quot;OFF&quot; state. &quot;OFF&quot; state is defined as a period of poor control of parkinsonian features with relatively poor overall function, such as worsening tremor, rigidity, balance or bradykinesia.
Data are no presented for the dose groups 0.04, 0.08, and 1.0 mg Lu AE04621 since no patients turned 'ON'.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of &quot;ON&quot; Time</measure>
    <time_frame>From dosing up to 24h post-dose</time_frame>
    <description>&quot;ON&quot; state is defined as a period of good control of parkinsonian features with relatively good overall function and mobility. Motor fluctuation assessments are patient-reported outcomes, and guidance will be given to the patients on how to complete them. Date and time will be registered when the patient turns to &quot;ON&quot; and &quot;OFF&quot; state. &quot;OFF&quot; state is defined as a period of poor control of parkinsonian features with relatively poor overall function, such as worsening tremor, rigidity, balance or bradykinesia. Outcome measured in minutes.
Data are no presented for the dose groups 0.04, 0.08, and 1.0 mg Lu AE04621 since no patients turned 'ON' following administration of Lu AE04621.</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>0.04 mg Lu AE04621</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients having received a dose of 0.04 mg, independent of which Cohort they belong to.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.08 mg Lu AE04621</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients having received a dose of 0.08 mg, independent of which Cohort they belong to.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.2 mg Lu AE04621</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients having received a dose of 0.2 mg, independent of which Cohort they belong to.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.4 mg Lu AE04621</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients having received a dose of 1.2 mg, independent of which Cohort they belong to.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.6 mg Lu AE04621</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients having received a dose of 0.6 mg, independent of which Cohort they belong to.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.8 mg Lu AE04621</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients having received a dose of 0.8 mg, independent of which Cohort they belong to.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 mg Lu AE04621</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients having received a dose of 1.0 mg, independent of which Cohort they belong to.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.2 mg Lu AE04621</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients having received a dose of 1.2 mg, independent of which Cohort they belong to.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.04 mg Lu AE04621</intervention_name>
    <description>0.04 mg dose group</description>
    <arm_group_label>0.04 mg Lu AE04621</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.08 mg Lu AE04621</intervention_name>
    <description>0.08mg dose group</description>
    <arm_group_label>0.08 mg Lu AE04621</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.2 mg Lu AE04621</intervention_name>
    <description>0.2 mg dose group</description>
    <arm_group_label>0.2 mg Lu AE04621</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.4 mg Lu AE04621</intervention_name>
    <description>0.4 mg dose group</description>
    <arm_group_label>0.4 mg Lu AE04621</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.6 mg Lu AE04621</intervention_name>
    <description>0.6 mg dose group</description>
    <arm_group_label>0.6 mg Lu AE04621</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.8 mg Lu AE04621</intervention_name>
    <description>0.8 mg dose group</description>
    <arm_group_label>0.8 mg Lu AE04621</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.0 mg Lu AE04621</intervention_name>
    <description>1.0 mg dose group</description>
    <arm_group_label>1.0 mg Lu AE04621</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.2 mg Lu AE04621</intervention_name>
    <description>1.2 mg dose group</description>
    <arm_group_label>1.2 mg Lu AE04621</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is diagnosed with idiopathic Parkinson Disease (consistent with the UK
             Parkinson`s Disease Society Brain Bank Criteria for the Diagnosis of PD).

          -  The patient's Hoehn and Yahr Staging score is ≤ 3 in the &quot;ON&quot; state.

          -  The patient experiences motor fluctuations with at least 2.5 hours of &quot;OFF&quot; periods in
             the awake time and has predictable morning &quot;OFF&quot; episodes, which have been consistent
             within the past 4 weeks.

          -  The patient currently has a good response to L-DOPA and has been receiving a stable
             dose of L-DOPA (≥3 doses per day of standard L-DOPA or ≥3 doses per day of Carbidopa
             and L-DOPA, Extended-Release Capsules) during at least four weeks prior to screening.

        Exclusion Criteria:

          -  The patient has cognitive impairment, defined as a Mini Mental State Examination(MMSE)
             score ≤ 26 at the Screening Visit.

          -  The patient has severe disabling dyskinesia

          -  The patient takes or has taken disallowed recent or concomitant medication (CYP2D6
             inhibitors, CYP 3A4 substrate, Dopamine agonists, 5 HT3 antagonists, Anti-viral
             (Amantadine))

        Other protocol defined inclusion and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US1251</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1126</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1352</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US1084</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>January 6, 2016</study_first_submitted>
  <study_first_submitted_qc>January 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2016</study_first_posted>
  <results_first_submitted>September 2, 2019</results_first_submitted>
  <results_first_submitted_qc>November 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 2, 2019</results_first_posted>
  <last_update_submitted>November 11, 2019</last_update_submitted>
  <last_update_submitted_qc>November 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Groups are overlapping the cohorts</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>Patients received 0.2 mg, 0.4 mg, and 0.6 mg Lu AE04621 on Days 1, 2, and 3, respectively</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>Patient received 0.2 mg, 0.4 mg, and 0.2 mg Lu AE04621 on Days 1, 2, and 3, respectively</description>
        </group>
        <group group_id="P3">
          <title>Group 3</title>
          <description>Patients received 0.4 mg, 0.6 mg, and 0.8 mg Lu AE04621 on Days 1, 2, and 3, respectively</description>
        </group>
        <group group_id="P4">
          <title>Group 4</title>
          <description>Patients received 0.2 mg, 0.4 mg, 0.6 mg, and 1.0 mg Lu AE04621 on Days 1, 2, 3, and 4, respectively</description>
        </group>
        <group group_id="P5">
          <title>Group 5</title>
          <description>Patients received 0.2 mg, 0.4 mg, 0.6 mg, and 1.2 mg Lu AE04621 on Days 1, 2, 3, and 4, respectively</description>
        </group>
        <group group_id="P6">
          <title>Group 6</title>
          <description>Patients received 0.2 mg, 0.4 mg, 0.4 mg, and 0.4 mg Lu AE04621 on Days 1, 2, 3, and 4, respectively</description>
        </group>
        <group group_id="P7">
          <title>Group 7</title>
          <description>Patient received 0.04 mg, 0.08 mg, 0.6 mg, and 0.6 mg Lu AE04621 on Days 1, 2, 3, and 4, respectively</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Total patient population</population>
      <group_list>
        <group group_id="B1">
          <title>Lu AE04621</title>
          <description>Patients having received 3 or 4 doses of Lu AE04621, ranging from 0.04 to 1.2 mg. Baseline measures are anlayzed on full patient group only.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability Based on the Safety Variables (Adverse Events, Clinical Safety Laboratory Tests, Vital Signs, Weight, and ECG)</title>
        <description>Number of patients with an adverse event</description>
        <time_frame>Baseline to day 11</time_frame>
        <population>Each patient received 3 or 4 doses of Lu AE04621. The overall number of participants analyzed in each group represents the number of patients having received a particular dose.</population>
        <group_list>
          <group group_id="O1">
            <title>0.04 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.04 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O2">
            <title>0.08 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.08 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.2 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O4">
            <title>0.4 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.4 mg, independent of which Cohort they belong to</description>
          </group>
          <group group_id="O5">
            <title>0.6 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.6 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O6">
            <title>0.8 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.8 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O7">
            <title>1.0 mg Lu AE04621</title>
            <description>Patients having received a dose of 1.0 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O8">
            <title>1.2 mg Lu AE04621</title>
            <description>Patients having received a dose of 1.2 mg, independent of which Cohort they belong to.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability Based on the Safety Variables (Adverse Events, Clinical Safety Laboratory Tests, Vital Signs, Weight, and ECG)</title>
          <description>Number of patients with an adverse event</description>
          <population>Each patient received 3 or 4 doses of Lu AE04621. The overall number of participants analyzed in each group represents the number of patients having received a particular dose.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve (AUC(0-24 Hours)) for Lu AE04621</title>
        <time_frame>From dosing to up to 24 hours after dosing</time_frame>
        <population>The overall number of participants analyzed in each group represents the number of dosing occasion at a particular dose, minus occasions with missing or unreliable data. The results are reported for the dose groups with sufficient data to calculate the parameter (missing dose groups for AUC(0-24 hours) are: 0.04, 0.08, 0.8, 1.0 and 1.2 mg)</population>
        <group_list>
          <group group_id="O1">
            <title>0.2 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.2 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O2">
            <title>0.4 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.4 mg Lu AE04621, independent of which cohort they belong to.</description>
          </group>
          <group group_id="O3">
            <title>0.6 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.6 mg Lu AE04621, independent of which cohort they belong to.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve (AUC(0-24 Hours)) for Lu AE04621</title>
          <population>The overall number of participants analyzed in each group represents the number of dosing occasion at a particular dose, minus occasions with missing or unreliable data. The results are reported for the dose groups with sufficient data to calculate the parameter (missing dose groups for AUC(0-24 hours) are: 0.04, 0.08, 0.8, 1.0 and 1.2 mg)</population>
          <units>pgxh/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212" spread="268"/>
                    <measurement group_id="O2" value="292" spread="219"/>
                    <measurement group_id="O3" value="309" spread="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Concentration (Cmax) for Lu AE04621</title>
        <time_frame>From dosing to up to 24 hours after dosing</time_frame>
        <population>Each patient received 3 or 4 doses of Lu AE04621. The overall number of participants analyzed in each group represents the number of dosing occasion at a particular dose, minus occasions with missing or unreliable data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.04 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.04 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O2">
            <title>0.08 mg LuAE04621</title>
            <description>Patients having received a dose of 0.08 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.2 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O4">
            <title>0.4 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.4 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O5">
            <title>0.6 mg Lu AE06421</title>
            <description>Patients having received a dose of 0.6 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O6">
            <title>0.8 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.8 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O7">
            <title>1.0 mg Lu AE04621</title>
            <description>Patients having received a dose of 1.0 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O8">
            <title>1.2 mg Lu AE04621</title>
            <description>Patients having received a dose of 1.2 mg, independent of which Cohort they belong to.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) for Lu AE04621</title>
          <population>Each patient received 3 or 4 doses of Lu AE04621. The overall number of participants analyzed in each group represents the number of dosing occasion at a particular dose, minus occasions with missing or unreliable data.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.52" spread="0"/>
                    <measurement group_id="O2" value="6.31" spread="0"/>
                    <measurement group_id="O3" value="48.6" spread="69.9"/>
                    <measurement group_id="O4" value="60.4" spread="57.3"/>
                    <measurement group_id="O5" value="52.8" spread="48.5"/>
                    <measurement group_id="O6" value="29.8" spread="31.3"/>
                    <measurement group_id="O7" value="55.9" spread="60.7"/>
                    <measurement group_id="O8" value="237" spread="67.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Elimination Half-life of Lu AE04621 in Plasma (t½)</title>
        <time_frame>From dosing to up to 24 hours after dosing</time_frame>
        <population>The overall number of participants analyzed in each group represents the number of dosing occasion at a particular dose, minus occasions with missing or unreliable data. The results are reported for the dose groups with sufficient data to calculate the parameter (missing dose groups for t½ are: 0.04, 0.08, 0.8, 1.0 and 1.2 mg)</population>
        <group_list>
          <group group_id="O1">
            <title>0.2 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.2 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O2">
            <title>0.4 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.4 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O3">
            <title>0.6 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.6 mg, independent of which Cohort they belong to.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Elimination Half-life of Lu AE04621 in Plasma (t½)</title>
          <population>The overall number of participants analyzed in each group represents the number of dosing occasion at a particular dose, minus occasions with missing or unreliable data. The results are reported for the dose groups with sufficient data to calculate the parameter (missing dose groups for t½ are: 0.04, 0.08, 0.8, 1.0 and 1.2 mg)</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.24" spread="2.43"/>
                    <measurement group_id="O2" value="5.00" spread="2.51"/>
                    <measurement group_id="O3" value="4.11" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Onset of &quot;ON&quot; Time After Lu AE04621 Administration</title>
        <description>&quot;ON&quot; state is defined as a period of good control of parkinsonian features with relatively good overall function and mobility. Motor fluctuation assessments are patient-reported outcomes, and guidance will be given to the patients on how to complete them. Date and time will be registered when the patient turns to &quot;ON&quot; and &quot;OFF&quot; state. &quot;OFF&quot; state is defined as a period of poor control of parkinsonian features with relatively poor overall function, such as worsening tremor, rigidity, balance or bradykinesia.
Data are no presented for the dose groups 0.04, 0.08, and 1.0 mg Lu AE04621 since no patients turned 'ON'.</description>
        <time_frame>From dosing to 90 minutes after dosing</time_frame>
        <population>Each patient received 3 or 4 doses of Lu AE04621. The overall number of participants analyzed in each group represents the number of dosing occasion at a particular dose. Data are no presented for the dose groups 0.04, 0.08, and 1.0 mg Lu AE04621 since no patients turned 'ON'.</population>
        <group_list>
          <group group_id="O1">
            <title>0.2 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.2 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O2">
            <title>0.4 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.4 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O3">
            <title>0.6 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.6 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O4">
            <title>0.8 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.8 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O5">
            <title>1.2 mg Lu AE04621</title>
            <description>Patients having received a dose of 1.2 mg, independent of which Cohort they belong to.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of &quot;ON&quot; Time After Lu AE04621 Administration</title>
          <description>&quot;ON&quot; state is defined as a period of good control of parkinsonian features with relatively good overall function and mobility. Motor fluctuation assessments are patient-reported outcomes, and guidance will be given to the patients on how to complete them. Date and time will be registered when the patient turns to &quot;ON&quot; and &quot;OFF&quot; state. &quot;OFF&quot; state is defined as a period of poor control of parkinsonian features with relatively poor overall function, such as worsening tremor, rigidity, balance or bradykinesia.
Data are no presented for the dose groups 0.04, 0.08, and 1.0 mg Lu AE04621 since no patients turned 'ON'.</description>
          <population>Each patient received 3 or 4 doses of Lu AE04621. The overall number of participants analyzed in each group represents the number of dosing occasion at a particular dose. Data are no presented for the dose groups 0.04, 0.08, and 1.0 mg Lu AE04621 since no patients turned 'ON'.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>dosing occasion when patient turned ON</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>dosing occasion when patient turned ON</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" spread="20.4"/>
                    <measurement group_id="O2" value="41" spread="28.6"/>
                    <measurement group_id="O3" value="39" spread="22.7"/>
                    <measurement group_id="O4" value="17" spread="0"/>
                    <measurement group_id="O5" value="20" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of &quot;ON&quot; Time</title>
        <description>&quot;ON&quot; state is defined as a period of good control of parkinsonian features with relatively good overall function and mobility. Motor fluctuation assessments are patient-reported outcomes, and guidance will be given to the patients on how to complete them. Date and time will be registered when the patient turns to &quot;ON&quot; and &quot;OFF&quot; state. &quot;OFF&quot; state is defined as a period of poor control of parkinsonian features with relatively poor overall function, such as worsening tremor, rigidity, balance or bradykinesia. Outcome measured in minutes.
Data are no presented for the dose groups 0.04, 0.08, and 1.0 mg Lu AE04621 since no patients turned 'ON' following administration of Lu AE04621.</description>
        <time_frame>From dosing up to 24h post-dose</time_frame>
        <population>Each patient received 3 or 4 doses of Lu AE04621. The overall number analyzed in each group represents the number of dosing occasion at a particular dose when patients turned 'ON'. Data are no presented for the dose groups 0.04, 0.08, and 1.0 mg Lu AE04621 since no patients turned 'ON'.</population>
        <group_list>
          <group group_id="O1">
            <title>0.2 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.2 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O2">
            <title>0.4 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.4 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O3">
            <title>0.6 mg Lu AE06421</title>
            <description>Patients having received a dose of 0.6 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O4">
            <title>0.8 mg Lu AE04621</title>
            <description>Patients having received a dose of 0.8 mg, independent of which Cohort they belong to.</description>
          </group>
          <group group_id="O5">
            <title>1.2 mg Lu AE04621</title>
            <description>Patients having received a dose of 1.2 mg, independent of which Cohort they belong to.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of &quot;ON&quot; Time</title>
          <description>&quot;ON&quot; state is defined as a period of good control of parkinsonian features with relatively good overall function and mobility. Motor fluctuation assessments are patient-reported outcomes, and guidance will be given to the patients on how to complete them. Date and time will be registered when the patient turns to &quot;ON&quot; and &quot;OFF&quot; state. &quot;OFF&quot; state is defined as a period of poor control of parkinsonian features with relatively poor overall function, such as worsening tremor, rigidity, balance or bradykinesia. Outcome measured in minutes.
Data are no presented for the dose groups 0.04, 0.08, and 1.0 mg Lu AE04621 since no patients turned 'ON' following administration of Lu AE04621.</description>
          <population>Each patient received 3 or 4 doses of Lu AE04621. The overall number analyzed in each group represents the number of dosing occasion at a particular dose when patients turned 'ON'. Data are no presented for the dose groups 0.04, 0.08, and 1.0 mg Lu AE04621 since no patients turned 'ON'.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203" spread="152.9"/>
                    <measurement group_id="O2" value="249" spread="98.9"/>
                    <measurement group_id="O3" value="270" spread="124.7"/>
                    <measurement group_id="O4" value="87" spread="0"/>
                    <measurement group_id="O5" value="401" spread="209.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to day 11</time_frame>
      <desc>Treatment-emergent adverse events are reported in this section.</desc>
      <group_list>
        <group group_id="E1">
          <title>0.04 mg Lu AE04621</title>
        </group>
        <group group_id="E2">
          <title>0.08 mg Lu AE04621</title>
        </group>
        <group group_id="E3">
          <title>0.2 mg Lu AE04621</title>
        </group>
        <group group_id="E4">
          <title>0.4 mg Lu AE04621</title>
        </group>
        <group group_id="E5">
          <title>0.6 mg Lu AE04621</title>
        </group>
        <group group_id="E6">
          <title>0.8 mg Lu AE04621</title>
        </group>
        <group group_id="E7">
          <title>1 mg Lu AE04621</title>
        </group>
        <group group_id="E8">
          <title>1.2 mg Lu AE04621</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Blunted affect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Yawning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Because of the limit of quantification, some missing and/or unreliable data prevented the calculation of some of the PK parameters (AUC0-24hours, apparent elimination half-life) for some of the dose groups.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Email contact via H. Lundbeck A/S</name_or_title>
      <organization>H. Lundbeck A/S</organization>
      <phone>+45 36301311</phone>
      <email>LundbeckClinicalTrials@Lundbeck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

